TBPH
Theravance Biopharma, Inc.
$17.01
-0.06%
2026-05-08
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Key Fundamentals
P/E Ratio
7.52
Forward P/E
12.38
EPS (TTM)
$2.23
ROE
50.2%
Revenue Growth (YoY)
15.0%
Profit Margin
104.3%
Debt/Equity
10.24
Price/Book
2.89
Beta
0.16
Market Cap
$864.4M
Avg Volume (10D)
289K
Recent Breakout Signals
No recent breakout signals detected for TBPH.
Recent Price Range (60 Days)
60D High
$20.40
60D Low
$13.08
Avg Volume
602K
Latest Close
$17.01
Get breakout alerts for TBPH
Sign up for Breakout Scanner to receive daily notifications when TBPH triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Theravance Biopharma, Inc. (TBPH) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TBPH daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TBPH operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.